IL‐1 plays a vital role in the pathophysiology of multiple sclerosis (MS), and inhibition of IL‐1 signaling in the BBB markedly ameliorates the severity of MS by downregulating the expression of ICAM‐1 and other proinflammatory mediators.20 This evidence concerns the gene ICAM1 and multiple sclerosis.